Selecta Biosciences Profit Margin

The latest profit margin for SELB is -8550.65% as of March 2026. That compares with -281.3% in the prior-year period — down 2939.7% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Selecta Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, SELB's profit margin moved from -281.3% to -8550.65% — a 2939.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Selecta Biosciences's valuation or profitability profile.

Against Healthcare companies, SELB currently prints -8550.65% for profit margin, while the sector average sits near 15.58%. That is roughly 54968.0% below the sector mean. Large gaps often invite a closer look at Selecta Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Selecta Biosciences converts resources into returns. At -8550.65%, SELB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -281.3% in the prior-year period — down 2939.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SELB's profit margin (-8550.65%), review year-over-year change from -281.3%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.